Fulgent Genetics EBITDA vs. Price To Book
| FLGT Stock | USD 18.33 0.46 2.57% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -46.6 M | Current Value -44.2 M | Quarterly Volatility 97.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.44 | 0.3612 |
|
|
For Fulgent Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fulgent Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fulgent Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fulgent Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fulgent Genetics over time as well as its relative position and ranking within its peers.
Fulgent |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.52) | Revenue Per Share 9.255 | Quarterly Revenue Growth (0.15) | Return On Assets (0.04) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fulgent Genetics Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Fulgent Genetics's current stock value. Our valuation model uses many indicators to compare Fulgent Genetics value to that of its competitors to determine the firm's financial worth. Fulgent Genetics is rated below average in ebitda category among its peers. It is rated below average in price to book category among its peers . At this time, Fulgent Genetics' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Fulgent Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fulgent Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Fulgent Genetics |
| = | (46.55 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Fulgent Genetics |
| = | 0.48 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Fulgent Price To Book Comparison
Fulgent Genetics is currently under evaluation in price to book category among its peers.
Fulgent Genetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Fulgent Genetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Fulgent Genetics will eventually generate negative long term returns. The profitability progress is the general direction of Fulgent Genetics' change in net profit over the period of time. It can combine multiple indicators of Fulgent Genetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.2 M | 1.3 M | |
| Operating Income | -72.7 M | -69.1 M | |
| Net Loss | -65 M | -61.7 M | |
| Income Before Tax | -174.1 M | -165.4 M | |
| Total Other Income Expense Net | -101.4 M | -96.3 M | |
| Net Income Applicable To Common Shares | 164.9 M | 101.5 M | |
| Net Loss | -167.8 M | -159.4 M | |
| Income Tax Expense | 1.2 M | 1.1 M | |
| Interest Income | 18.6 M | 19.5 M | |
| Net Interest Income | 18.6 M | 19.5 M | |
| Non Operating Income Net Other | 5.8 M | 6.1 M | |
| Change To Netincome | 86.8 M | 91.1 M | |
| Net Loss | (5.63) | (5.35) | |
| Income Quality | (0.16) | (0.17) | |
| Net Income Per E B T | 0.96 | 1.45 |
Fulgent Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Fulgent Genetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Fulgent Genetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Fulgent Genetics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Fulgent Genetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Fulgent Genetics position
In addition to having Fulgent Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.